Boston Scientific (BSX) Stock
Global medical device company powering heart and urology care. Here's the price, business snapshot, and what's worth knowing about Boston Scientific in July 2026.
Boston Scientific (BSX) is a global medical‑devices company with a market capitalisation of about $148.03bn, selling products used in cardiology, rhythm management, peripheral interventions, endoscopy and urology. Investors should know it earns recurring revenue from disposable devices and procedure-driven demand, backed by ongoing R&D and product launches. The business benefits from demographic trends such as an ageing population and wider access to minimally invasive therapies, yet it faces stiff competition from large peers, reimbursement and regulatory pressures, and occasional product or legal setbacks. Financial performance can be influenced by procedure volumes, hospital capital spending, foreign exchange and the success of new technologies. For investors, Boston Scientific offers exposure to healthcare innovation but also to sector-specific operational and regulatory risks. This is general educational information, not personalised advice — values can rise and fall and past performance is not a reliable guide to future returns.
Why It’s Moving
BSX Shares Hold Near $44.90 as Investors Gauge Healthcare Sector Strength Amid Final Fed Rate Meeting
- Boston Scientific shares are trading near $44.90 amid a busy Wall Street week dominated by the Federal Reserve's final rate meeting under outgoing Chair Jerome Powell, which is shaping investor sentiment across the healthcare sector.
- The stock is currently positioned in the Healthcare sector, which has underperformed year-to-date with a -6% ranking as of March 31, 2026, reflecting broader macro pressure on medical device valuations.
- Despite the sector slump, BSX maintains a P/E ratio of 18.77 and a market cap of $66.54B, suggesting investors view the current dip as a potential entry point for long-term recovery as earnings season begins for major tech and healthcare firms.
BSX Shares Hold Near $44.90 as Investors Gauge Healthcare Sector Strength Amid Final Fed Rate Meeting
- Boston Scientific shares are trading near $44.90 amid a busy Wall Street week dominated by the Federal Reserve's final rate meeting under outgoing Chair Jerome Powell, which is shaping investor sentiment across the healthcare sector.
- The stock is currently positioned in the Healthcare sector, which has underperformed year-to-date with a -6% ranking as of March 31, 2026, reflecting broader macro pressure on medical device valuations.
- Despite the sector slump, BSX maintains a P/E ratio of 18.77 and a market cap of $66.54B, suggesting investors view the current dip as a potential entry point for long-term recovery as earnings season begins for major tech and healthcare firms.
When is the next earnings date for BOSTON SCIENTIFIC CORP (BSX)?
Boston Scientific (BSX) is estimated to release its next earnings report on July 29, 2026, covering the second quarter of 2026. This date is based on the company’s historical reporting schedule, as the company has not yet officially confirmed the release. The upcoming report will detail financial results for the period ending June 30, 2026, including revenue and earnings per share projections. Analysts expect the conference call to occur at 8:00 AM ET on the same day.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Boston Scientific's stock, with a target price significantly higher than its current price.
Financial Health
Boston Scientific is performing well with strong profits and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring BSX
Dow 48,000 Rally: Bull Market Risks & Opportunities
The Dow Jones Industrial Average has surpassed 48,000 for the first time, driven by strong performance in the healthcare and financial sectors. This milestone suggests a bullish outlook on the U.S. economy, creating opportunities among the leading blue-chip companies.
Published: 14 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketMedTech Stocks: Brazil Market Risks & Opportunities
Brazil's growing demand for advanced healthcare presents an opportunity to modernize its medical infrastructure and improve patient outcomes. This basket offers exposure to the leading US and European companies supplying Brazil with robotic surgery systems, AI diagnostics, and innovative medical devices.
Published: 21 October 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: 14 October 2025
Explore BasketStagflation Standouts
This collection features stocks and assets carefully selected by professional analysts to potentially outperform during stagflation periods. These defensive investments have already shown strength while the broader market struggles, making them worth consideration for economic uncertainty ahead.
Published: 19 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Procedure demand tailwind
An ageing population and rising access to minimally invasive procedures can support long‑term demand, though volumes can ebb with hospital spending cycles.
Innovation and R&D
Regular product launches and technological improvements drive share gains and pricing power, but new products must clear regulatory and commercial hurdles.
Regulatory and market risks
Exposure to reimbursement, recalls and litigation means performance can be volatile; investors should weigh potential returns against these sector‑specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
